The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis.
| Title | The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. |
| Publication Type | Journal Article |
| Year of Publication | 2010 |
| Authors | Farmaki, E., Kanakoudi-Tsakalidou F., Spoulou V., Trachana M., Pratsidou-Gertsi P., Tritsoni M., & Theodoridou M. |
| Journal | Vaccine |
| Volume | 28 |
| Issue | 31 |
| Pagination | 5109-13 |
| Date Published | 2010 Jul 12 |
| ISSN | 1873-2518 |
| Keywords | Adolescent, Antibodies, Bacterial, Antirheumatic Agents, Arthritis, Juvenile, Child, Child, Preschool, Cyclosporine, Female, Humans, Male, Methotrexate, Pneumococcal Vaccines, Prednisone, Tumor Necrosis Factor-alpha, Vaccines, Conjugate |
| Abstract | Our aim was to study the effect of anti-TNF treatment on immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Thirty-one children (mean age:12.9+/-4.6 years) treated with anti-TNFs plus Disease Modifying Anti-Rheumatic Drugs (DMARDs) and 32 age-matched children treated only with DMARDs were vaccinated with two doses of PCV7. After the first vaccine dose geometric mean titers (GMTs) were significantly increased for all vaccine serotypes (p<0.0001) in both groups and were found to be protective (>0.35microg/ml) in 87-100% of all children, depending on the serotype. Children receiving anti-TNFs achieved a significantly lower GMTs against serotypes 4, 14 and 23F (p<0.05). A >or=4-fold increase of the baseline titers to >or=5 vaccine serotypes was observed in 50% and 75% of the anti-TNF and control patients, respectively (p=0.0697). No patient developed vaccine-associated serious adverse events or disease flares. |
| DOI | 10.1016/j.vaccine.2010.03.080 |
| Alternate Journal | Vaccine |
| PubMed ID | 20470802 |
